Pharma wary as India proposes Central Drugs Authority, tighter trial rules
This article was originally published in SRA
Executive Summary
India has outlined a clutch of proposals in the regulatory field including the setting up of a new Central Drugs Authority, penal provisions for those flouting clinical trial norms, and a specific set of regulations for medical devices, as part of the Drugs and Cosmetics (Amendment) Bill 20131.